Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Kaddurah Daouk, Rima ^a   Yuan, Peixiong ^b   Boyle, Stephen H ^a   Matson, Wayne ^c   Wang, Zhi ^d   Zeng, Zhao Bang ^d   Zhu, Hongjie ^d   Dougherty, George G ^c,e   Yao, Jeffrey K ^c,e   Chen, Guang ^b   Guitart, Xavier ^b   Carlson, Paul J ^b   Neumeister, Alexander ^b,h   Zarate, Carlos ^b   Krishnan, Ranga R ^a,f   Manji, Husseini K ^b   Drevets, Wayne ^b,g  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

^g LAUREATE INSTITUTE FOR BRAIN RESEARCH   (United States)

^h NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOGENIC AMINE;

ADULT; ARTICLE; BIOSYNTHESIS; CASE CONTROL STUDY; CEREBROSPINAL FLUID; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; METABOLOME; MIDDLE AGED; MULTIVARIATE ANALYSIS; REMISSION; SEVERITY OF ILLNESS INDEX;

ADULT; BIOGENIC MONOAMINES; BIOSYNTHETIC PATHWAYS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; METABOLOME; MIDDLE AGED; MULTIVARIATE ANALYSIS; REMISSION, SPONTANEOUS; SEVERITY OF ILLNESS INDEX;

EID: 84867031949     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00667     Document Type: Article

References (79)

1. Delgado, P. L. Common pathways of depression and pain. J Clin Psychiatry 65 Suppl 12, 16-19 (2004).
2. Delgado, P. L. & Moreno, F. A. Role of norepinephrine in depression. J Clin Psychiatry 61 Suppl 1, 5-12 (2000). (Pubitemid 30124144)
3. Brambilla, P., Perez, J., Barale, F., Schettini, G. & Soares, J. C. GABAergic dysfunction in mood disorders. Mol Psychiatry 8, 721-737, 715 (2003).
4. Sanacora, G. & Saricicek, A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets 6, 127-140 (2007). (Pubitemid 46681773)
5. Kaddurah-Daouk, R. & Krishnan, K. R. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34, 173-186 (2009).
6. Kaddurah-Daouk, R., Kristal, B. S.&Weinshilboum, R.M.Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48, 653-683 (2008). (Pubitemid 351738167)
7. Kristal, B. S., Shurubor, Y. I., Kaddurah-Daouk, R.&Matson,W. R.Metabolomics in the study of aging and caloric restriction. Methods Mol Biol 371, 393-409 (2007). (Pubitemid 350183437)
8. Kristal, B. S., Shurubor, Y. I., Kaddurah-Daouk, R. & Matson, W. R. Highperformance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol 358, 159-174 (2007).
9. Lindon, J. C., Holmes, E. & Nicholson, J. K. Metabonomics in pharmaceutical R&D. Febs J 274, 1140-1151 (2007).
10. Ji, Y. et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomicsinformed pharmacogenomics. Clin Pharmacol Ther 89, 97-104, 10.1038/clpt.2010.250 (2011).
11. Paige, L. A., Mitchell, M. W., Krishnan, K. R., Kaddurah-Daouk, R. & Steffens, D. C. A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry 22, 418-423 (2007). (Pubitemid 46831684)
12. Steffens, D. C. et al. Metabolomic differences in heart failure patients with and without major depression. J Geriatr Psychiatry Neurol 23, 138-146 (2010).
13. Kaddurah-Daouk, R. et al.Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 12, 934-945 (2007). (Pubitemid 47482696)
14. Yao, J. K. et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry (2009).
15. Wu, J., An, Y., Yao, J., Wang, Y. & Tang, H. An optimised sample preparation method for NMR-based faecal metabonomic analysis. Analyst 135, 1023-1030 (2010).
16. Johansen, K. K. et al. Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One 4, e7551 (2009).
17. Bogdanov, M. et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131, 389-396 (2008). (Pubitemid 351197614)
18. Lan, M. J. et al. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry 14, 269-279 (2009).
19. Wikoff, W. R., Pendyala, G., Siuzdak, G. & Fox, H. S. Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J Clin Invest 118, 2661-2669 (2008). (Pubitemid 351949793)
20. Asberg, M. et al. CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 69, 201-219 (1984). (Pubitemid 14155019)
21. Traskman-Bendz, L., Asberg, M., Bertilsson, L. & Thoren, P. CSF monoamine metabolites of depressed patients during illness and after recovery. Acta Psychiatr Scand 69, 333-342 (1984). (Pubitemid 14166363)
22. Mayberg, H. S. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 9, 471-481 (1997). (Pubitemid 27363950)
23. Van Praag, H. M. New evidence of serotonin-deficient depressions. Neuropsychobiology 3, 56-63 (1977).
24. Ferrier, I. N. et al. Postmortem neurochemical studies in depression. Ann N Y Acad Sci 487, 128-142 (1986).
25. McKeith, I. G. et al. 5-HT receptor binding in post-mortem brain from patients with affective disorder. J Affect Disord 13, 67-74 (1987). (Pubitemid 17138090)
26. van Praag, H. M. & de Haan, S. Central serotonin deficiency-a factor which increases depression vulnerability? Acta Psychiatr Scand Suppl 280, 89-96 (1980). (Pubitemid 10055007)
27. Vestergaard, P. et al. Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders. Acta Psychiatr Scand 58, 88-96 (1978). (Pubitemid 8397271)
28. Lee, D. S. et al. The implications of human metabolic network topology for disease comorbidity. Proc Natl Acad Sci USA 105, 9880-9885 (2008).
29. Nordin, C. Relationships between clinical symptoms and monoamine metabolite concentrations in biochemically defined subgroups of depressed patients. Acta Psychiatr Scand 78, 720-729 (1988). (Pubitemid 19027342)
30. Inoue, T., Tsuchiya, K. & Koyama, T. Regional changes in dopamine and serotonin activation with various intensity of physical and psychological stress in the rat brain. Pharmacol Biochem Behav 49, 911-920 (1994). (Pubitemid 24376030)
31. Kennedy, N. & Paykel, E. S. Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord 80, 135-144 (2004). (Pubitemid 38597136)
32. Santesso, D. L. et al. Enhanced negative feedback responses in remitted depression. Neuroreport 19, 1045-1048 (2008).
33. Hasler, G. et al. Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry 65, 521-531 (2008). (Pubitemid 351645048)
34. Hasler, G. et al. Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder. Biol Psychiatry 66, 201-205 (2009).
35. Neumeister, A., Young, T.&Stastny, J. Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter. Psychopharmacology (Berl) 174, 512-524 (2004). (Pubitemid 39119340)
36. Delgado, P. L. Depression: the case for a monoamine deficiency. J Clin Psychiatry 61 Suppl 6, 7-11 (2000). (Pubitemid 30217405)
37. Moreno, F. A. et al. CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls. Eur Neuropsychopharmacol 20, 18-24 (2010).
38. Carpenter, L. L., Anderson, G. M., Siniscalchi, J. M., Chappell, P. B. & Price, L. H. Acute changes in cerebrospinal fluid 5-HIAA following oral paroxetine challenge in healthy humans. Neuropsychopharmacology 28, 339-347 (2003).
39. Lundmark, J., Walinder, J., Alling, C.,Manniche, P. M.&Dalgaard, L. The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients. Eur Neuropsychopharmacol 4, 1-6 (1994). (Pubitemid 24087020)
40. Malone, K. M. et al. Fenfluramine challenge test as a predictor of outcome inmajor depression. Psychopharmacol Bull 29, 155-161 (1993). (Pubitemid 23311518)
41. Martensson, B. et al. Effects of clomipramine treatment on cerebrospinal fluid monoamine metabolites and platelet 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder. Acta Psychiatr Scand 83, 125-133 (1991).
42. Sheline, Y., Bardgett, M. E. & Csernansky, J. G. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 17, 11-14 (1997). (Pubitemid 27047256)
43. Backman, J., Alling, C., Alsen, M., Regnell, G. & Traskman-Bendz, L. Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatment. Eur Neuropsychopharmacol 10, 341-349 (2000).
44. Bhagwagar, Z. & Cowen, P. J. 'It's not over when it's over': persistent neurobiological abnormalities in recovered depressed patients. Psychol Med 38, 307-313 (2008). (Pubitemid 351311671)
45. Stockmeier, C. A. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatr Res 37, 357-373 (2003). (Pubitemid 36808810)
46. Melfi, C. A. et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 55, 1128-1132 (1998). (Pubitemid 28558286)
47. Claxton, A. J., Li, Z. & McKendrick, J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry 177, 163-168 (2000). (Pubitemid 30624829)
48. van Praag, H. & de Hann, S. Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Res 3, 75-83 (1980). (Pubitemid 11247308)
49. Drexhage RC, K. E., Padmos RC, Heul-Nieuwenhuijzen, L. & Beumer, W. V. M. Drexhage HA Themononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 10.
50. Wichers, M. C. et al. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 10, 538-544 (2005). (Pubitemid 40897037)
51. Capuron, L. et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 54, 906-914 (2003). (Pubitemid 37311353)
52. Kling, M. A. et al. Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry 62, 309-313 (2007). (Pubitemid 47449633)
53. Hasler, G., Drevets, W. C., Manji, H. K. & Charney, D. S. Discovering endophenotypes for major depression. Neuropsychopharmacology 29, 1765-1781 (2004). (Pubitemid 39336788)
54. Roy, A. et al. Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression. Am J Psychiatry 143, 1539-1545 (1986). (Pubitemid 17196196)
55. Cools R., Nakamura K., Daw N.D., Serotonin and Dopamine: Unifying Affective.Activational, and Decision Functions. Neuropsychopharmacology, doi: j doi:10.1038/npp.2010.121 (2010).
56. McGowan, P. O. & Kato, T. Epigenetics in mood disorders. Environ Health Prev Med 13, 16-24 (2008).
57. Cantoni, G. L., Mudd, S. H. & Andreoli, V. Affective disorders and Sadenosylmethionine: a new hypothesis. Trends Neurosci 12, 319-324 (1989). (Pubitemid 19207614)
58. Kagan, B. L., Sultzer, D. L., Rosenlicht, N. & Gerner, R. H. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 147, 591-595 (1990). (Pubitemid 20153428)
59. Abdolmaleky, H. M. et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 15, 3132-3145 (2006). (Pubitemid 44607800)
60. Abdolmaleky, H. M., Smith, C. L., Zhou, J. R. & Thiagalingam, S. Epigenetic alterations of the dopaminergic system in major psychiatric disorders. Methods Mol Biol 448, 187-212 (2008).
61. Dempster, E. L., Mill, J., Craig, I.W. & Collier, D. A. The quantification of COMT mRNA in post mortem cerebellum tissue: diagnosis, genotype, methylation and expression. BMC Med Genet 7, 10 (2006).
62. Krishnan, V. et al.Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131, 391-404 (2007). (Pubitemid 47576141)
63. Cui, J., Shao, L., Young, L. T. &Wang, J. F. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144, 1447-1453 (2007). (Pubitemid 46123817)
64. Frey, B. N. et al. Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res 1097, 224-229 (2006). (Pubitemid 44041287)
65. Ozcan, M. E., Gulec, M., Ozerol, E., Polat, R. & Akyol, O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 19, 89-95 (2004). (Pubitemid 38316767)
66. Tsaluchidu, S., Cocchi, M., Tonello, L.&Puri, B. K. Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry 8 Suppl 1, S5 (2008).
67. Gawryluk, J.W., Wang, J. F., Andreazza, A. C., Shao, L. & Young, L. T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol, 1-8 (2011).
68. Agren, H., Niklasson, F. & Hallgren, R. Brain purinergic activity linked with depressive symptomatology: hypoxanthine and xanthine in CSF of patients with major depressive disorders. Psychiatry Res 9, 179-189 (1983). (Pubitemid 13044662)
69. Niklasson, F., Agren, H. & Hallgren, R. Purine and monoamine metabolites in cerebrospinal fluid: parallel purinergic and monoaminergic activation in depressive illness? J Neurol Neurosurg Psychiatry 46, 255-260 (1983). (Pubitemid 13110493)
70. LeWitt, P. A. et al. Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group. Neurology 42, 2111-2117 (1992).
71. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition. Washington, DC American Psychiatric Association; 1994.
72. First, MB, Spitzer, R. L., Gibbon, M & William, J. B. W. Structured Clinical Interview fpr DSM-IV-TR Axis 1 disorders, Research Version, Patient Edition (SCID-I/P) New York, NY: New York State Psychiatric Institute, Biometric research; 2002. 73 Maxwell, M. (Bethesda, MD, 1992).
73. Maxwell, E. Family Interview for Genetic Studies (FIGS): A Manual For FIGS, Bethesda MD: Clinical Neurogenetics Branch, Intrmural Research Program National Institute of Mental Health; 1992.
74. Rozen, S. et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1, 101-108 (2005). (Pubitemid 40778831)
75. Kristal, B. S., Vigneau-Callahan, K. E. & Matson, W. R. Simultaneous analysis of the majority of low-molecular-weight, redox-active compounds from mitochondria. Anal Biochem 263, 18-25 (1998). (Pubitemid 28445419)
76. Shi, W. & Palmer, C. P. Effect of pendent group structures on the chemical selectivity and performance of sulfonated copolymers as novel pseudophases in electrokinetic chromatography. Electrophoresis 23, 1285-1295 (2002). (Pubitemid 34567359)
77. Vigneau-Callahan, K. E., Shestopalov, A. I., Milbury, P. E., Matson, W. R. & Kristal, B. S. Characterization of diet-dependent metabolic serotypes: analytical and biological variability issues in rats. J Nutr 131, 924S-932S (2001). (Pubitemid 32199171)
78. Lehmann, E. L. Nonparametrics: Statistical Methods Based on Ranks. Oakland, Springer Science & Business Media, LLC., New York, NY 5, 202-249 (2006).
79. Barrett, T. Computations using analysis of covariance. Computational Statistics 3, 260-268 (2011).